High-Dose Vitamin B3 Shows Early Promise Against Deadly Glioblastoma
A small clinical trial finds 82% of glioblastoma patients remained progression-free at six months when high-dose niacin was added to standard care.
Summary
Researchers at the University of Calgary are testing high-dose vitamin B3 (niacin) as an add-on to standard glioblastoma treatment. Glioblastoma is an aggressive brain cancer that suppresses the immune system, preventing it from attacking tumor cells. Early results from a combined Phase I/II trial are encouraging: 82% of patients remained progression-free six months after diagnosis. The theory is that niacin can rejuvenate immune cells that the tumor has suppressed, restoring their ability to target and destroy cancer cells. The approach originated in mouse studies showing extended survival with niacin treatment. Researchers are using a controlled-release form of niacin alongside standard chemotherapy and radiotherapy. While the results are promising, the trial is small and larger studies are needed before any firm conclusions can be drawn about effectiveness and safety.
Detailed Summary
Glioblastoma is one of the most lethal brain cancers known, with standard treatment — surgery, radiation, and chemotherapy — rarely offering a cure. Even after aggressive intervention, the cancer typically returns. Researchers at the University of Calgary believe a widely available, inexpensive nutrient may help change that equation: high-dose vitamin B3, or niacin.
The central biological problem with glioblastoma is that the tumor actively suppresses the immune system, disarming the very cells that might otherwise recognize and destroy cancer. Neuroscientist Wee Yong and oncologist Gloria Roldan Urgoiti are investigating whether niacin can reverse this immune suppression. Their hypothesis, supported by preclinical mouse studies that showed extended survival, is that niacin rejuvenates exhausted or suppressed immune cells, restoring their capacity to attack the tumor.
In the current combined Phase I/II clinical trial, patients receive controlled-release niacin alongside standard chemotherapy and radiotherapy. The early signal is striking: 82% of enrolled patients remained progression-free at six months, a notable result for a cancer with such a grim prognosis. The trial's Phase I component focuses on safety and optimal dosing, while Phase II begins evaluating clinical benefit.
For patients like 55-year-old Ed Waldner, who was diagnosed after experiencing fatigue and gait changes, participation in the trial offers both practical hope and psychological grounding. His experience underscores how limited current options feel for glioblastoma patients after surgery.
Despite the encouraging numbers, critical caveats apply. The trial is small, and without a randomized control group the 82% figure cannot yet be attributed confidently to niacin. Larger, randomized studies are essential to confirm both efficacy and long-term safety at high doses. Still, the accessibility and low cost of vitamin B3 make this a compelling research direction in brain cancer immunotherapy.
Key Findings
- 82% of glioblastoma patients in the trial remained progression-free at six months when given high-dose niacin alongside standard treatment.
- Glioblastoma suppresses the immune system; niacin may rejuvenate those suppressed immune cells to attack tumor cells.
- The approach emerged from mouse studies where niacin treatment extended survival in glioblastoma models.
- The trial uses controlled-release niacin added to standard chemotherapy and radiotherapy, testing safety and early efficacy.
- Results are preliminary; larger randomized trials are needed before niacin can be recommended as a standard add-on therapy.
Methodology
This is a news report summarizing an ongoing combined Phase I/II clinical trial conducted at the University of Calgary. The source is a university press release via ScienceDaily, which is credible but should be verified against the primary published trial data. Evidence is early-stage, with a small patient sample and no explicit randomized control arm described.
Study Limitations
The trial is small with no described randomized control group, making it difficult to attribute the 82% progression-free rate solely to niacin. Full peer-reviewed publication of the trial data is not referenced, limiting independent verification. High-dose niacin carries known side effects, and long-term safety in this population remains to be established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: